Abstract
The article describe modelling efforts for evaluating the current level of COVID-19 infections in India, using exponential model. The Data from 15 march 2020 to 30 April 2020 are used for validating the model, where intrinsic rise rate is kept constant. It is observed that some states of India, like MAharastra, Gujarat and Delhi have a much higher daily infection cases. This is modelled by assuming an initial higher infections, keeping rise rate same. The sudden outbursts are captured using offset of values for these three states. Data from other states like Madhya Pradesh, Uttar Pradesh and Rajasthan are also analysed and they are found to be following the same constants as India is following. Worldwide, many attempts are made to predict outburst of COVID-19 and in the model, described in this paper, turning point is not predicted, as cases in India are still rising. The developed model is based on daily confirmed infections and not on cumulative infections and rationalization is carried out for the population of various regions, while predicting infections for various states. Assigning a decay constant at this stage will be a premature exercise and keeping that in mind, exponential model predicts that India will attain 1 lakh case by 15 May 2020. The figure of 2 lakh and 3 lakh will be attained on 22 May 2020 and 26 May 2020, respectively.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The Study was carried out as an independent freelance work, involving non-clinical modeling aspects.
Funding Statement
No funding is received for conducting this research
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data is collected from Googlenews about status of daily infections in India and the same is mentioned as one of the references
